Navigation Links
DOR BioPharma to Present at the Rodman & Renshaw Annual Global Investor Healthcare Conference
Date:9/3/2009

nes against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). Factors affecting the development and use of DOR201 and LPM(TM) are similar to those affecting orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 1
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eiger BioPharmaceuticals Appoints Paul Truex to Board of Directors
2. DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
3. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
5. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
6. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
7. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
8. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
9. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
(Date:4/16/2015)... Md. , April 16, 2015  RegeneRx ... today announced its U.S. joint venture with G-treeBNT ... a phase 3 clinical trial for the orphan ... confirmatory trial for dry eye syndrome (DES) in ... preservative-free eye drops, RGN-259/GBT201, this year.  Each of ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 /PRNewswire/ ... and development of therapeutic antibodies, today announced ... (IL-36R) antibody program into IND-enabling studies. The ... a novel treatment for generalized pustular psoriasis ... high unmet medical need. ANB019 is wholly owned ...
(Date:4/16/2015)... , Switzerland , April ... (Debiopharm), part of Debiopharm Group ™ , a ... that target unmet medical needs as well ... data on the investigational compounds Debio 1143 (SMAC ... be presented at the 2015 Annual meeting ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
... its last few months, 2004 delivered some promising advances in ... the state has set in motion public initiatives to help ... the Wisconsin Technology Network just turned two. To celebrate, here ... eye on leading CIOs ,Wisconsins CIOs continue to push ...
... above Ophir Creek in Alaska. Credit: Alaska Division ... rural Alaskan knowledge can now spread globally thanks ... Sensing Center and the Alaska Division of Geological ... or Mapping Technology Experiences with Alaska's Cultural Heritage, ...
... the Wisconsin Legislatures top spot from 1985 to 1991, ... his book, The Art of Legislative Politics. , ,A ... for the common good. A legislature can also be ... Legislature over the past 10 years has worn both ...
Cached Biology Technology:2004 in review: Editors picks 22004 in review: Editors picks 3MapTeach project spreads Alaskan geographic knowledge online 2MapTeach project spreads Alaskan geographic knowledge online 3In the Wisconsin Legislature, the promise of a productive session 2In the Wisconsin Legislature, the promise of a productive session 3
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... substances which can be stimulated to emit light ... diagnosis. Fluorescence can be used for instance to analyze ... in cells and tissues, to follow metabolic pathways and ... particular importance is the combination of fluorescence imaging with ...
... Jason Goldstein checks his lobster traps in New ... for tasty crustaceans to sell. Instead, the University of ... transmitters and tracking their migrations year-round. ... and into Great Bay throughout the past two years. ...
... Why are some people fast learners? Can we teach everybody ... Rice University research project recently funded by the National Science ... technology to codify learning systems in ways that can be ... surgery. Two Rice professors, Marcia O,Malley and Michael Byrne, ...
Cached Biology News:Novel technique for fluorescence tomography of tumors in living animals 2UNH researchers track lobster migrations to improve population estimates 2UNH researchers track lobster migrations to improve population estimates 3Wii bit of fun at Rice University has serious intent 2
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
...
... pleased to offer the ATTO-TAG series ... of primary amines. Developed by Novotny ... ATTO-TAG reagents are similar to the ... and anthracene-2,3-dicarboxaldehyde, all of which are ...
Troponin I (22B11)...
Biology Products: